Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.27) by 133.33 percent. This is a 26 percent decrease over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $347.000 thousand which beat the analyst consensus estimate of $325.000 thousand by 6.77 percent. This is a 60.75 percent decrease over sales of $884.000 thousand the same period last year.